Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-711 · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
BOR is defined as partial response (PR) or better per investigator review according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
| Arm | Type | Description |
|---|---|---|
| Part 1: ABBV-711 Monotherapy Dose Escalation | EXPERIMENTAL | Participants will receive ABBV-711 in escalating doses alone, as part of the 5 year study duration. |
| Part 2a: ABBV-711 Monotherapy Dose Expansion | EXPERIMENTAL | Participants will receive ABBV-711 dose A alone, as part of the 5 year study duration. |
| Part 2b: ABBV-711 Monotherapy Dose Expansion | EXPERIMENTAL | Participants will receive ABBV-711 dose B alone, as part of the 5 year study duration. |
| Part 3: ABBV-711 + BudigalimabDose Escalation | EXPERIMENTAL | Participants will receive ABBV-711 in escalating doses in combination with budigalimab, as part of the 5 year study duration. |
| Part 4a: ABBV-711 Budigalimab Dose Expansion | EXPERIMENTAL | Participants will receive ABBV-711 dose A in combination with budigalimab, as part of the 5 year study duration. |
| Part 4b: ABBV-711 Budigalimab Dose Expansion | EXPERIMENTAL | Participants will receive ABBV-711 dose B in combination with budigalimab, as part of the 5 year study duration. |
| Name | Type | Description |
|---|---|---|
| ABBV-711 | DRUG | Oral Tablet |
| Budigalimab | DRUG | Intravenous Infusion |
Inclusion Criteria: * Must have progressed on or after standard of care therapy and have no curative therapy available (participants who have refused, are considered ineligible for or are intolerant to standard of care therapy are eligible). * Received programmed cell death protein 1 (PD-1)/program...
ABBV-711 is an investigational small molecule being developed for the treatment of advanced squamous tumors. It is currently in Phase 1 clinical development and is being studied as a monotherapy and in combination with budigalimab (ABBV-181) in adults with advanced squamous tumors.
The molecular target of ABBV-711 has not been disclosed. It is a small molecule being studied for its effects on disease activity in advanced squamous tumors, but its specific mechanism of action has not been publicly detailed.
ABBV-711 is being developed by AbbVie Inc. (NYSE: ABBV). The company is conducting a Phase 1 clinical trial to evaluate the drug in adults with advanced squamous tumors.
ABBV-711 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial is currently recruiting participants to assess its safety, tolerability, and pharmacokinetics.
ABBV-711 is being evaluated in a Phase 1 trial with the identifier NCT07241039. This study assesses adverse events, change in disease activity, and how oral ABBV-711 tablets move through the body as a monotherapy and in combination with intravenously infused budigalimab (ABBV-181) in adults with advanced squamous tumors.
No, ABBV-711 is not the same as budigalimab. ABBV-711 is an oral small molecule being studied as a monotherapy and in combination with budigalimab (ABBV-181), which is a separate investigational drug administered intravenously. The two agents are being evaluated together in a Phase 1 trial.